Success Metrics

Completion Rate
0%(0/1)
Active Trials
5(71%)
Terminated
1(14%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
3
43%
Ph not_applicable
1
14%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Terminated(1)
Other(1)

Detailed Status

Recruiting3
Active, not recruiting2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
N/A1 (14.3%)

Trials by Status

unknown114%
recruiting343%
active_not_recruiting229%
terminated114%

Recent Activity

5 active trials
Showing 5 of 7
active_not_recruitingphase_2

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

NCT04217278
recruitingphase_1

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

NCT05558124
recruitingphase_1

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

NCT03826992
recruitingphase_1

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

NCT05024552
active_not_recruitingphase_2

Vyxeos for Induction of Low- or Intermediate-risk.

NCT05599360
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04217278Phase 2

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Active Not Recruiting
NCT05558124Phase 1

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Recruiting
NCT03826992Phase 1

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Recruiting
NCT05024552Phase 1

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Recruiting
NCT05599360Phase 2

Vyxeos for Induction of Low- or Intermediate-risk.

Active Not Recruiting
NCT05801835Not Applicable

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Unknown
NCT04425655Phase 2

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7